INTRODUCTION {#s1}
============

Shwachman--Diamond syndrome (SDS; OMIM 260400) is an autosomal recessive condition that is characterized by a triad of exocrine pancreatic insufficiency, bone marrow dysfunction, and metaphyseal dysostosis ([@MCS003046TANC3]; [@MCS003046TANC23]; [@MCS003046TANC4]). Most patients present as infants with growth failure due to pancreatic insufficiency and/or recurrent infections due to neutropenia ([@MCS003046TANC8]), whereas the metaphyseal changes leading to short stature typically become evident in childhood or later ([@MCS003046TANC16]). The pancreatic dysfunction varies in severity, and a subset of patients may show improvement in pancreatic function in late childhood ([@MCS003046TANC11]). Hematologic abnormalities in patients with SDS vary in type of lineage affected, as well as severity ([@MCS003046TANC8]). Neutropenia and anemia are the most common bone marrow abnormalities, but thrombocytopenia and pancytopenia may also be seen ([@MCS003046TANC8]). Metaphyseal chondrodysplasia seen in SDS is present in all patients but shows variability, even within the same family ([@MCS003046TANC16]). Skeletal findings are typically symmetrical and are more severe in the lower limbs. By age 2 yr, metaphyseal changes seen include broadening of the metaphyses with characteristic lucent and sclerotic changes, which disappear when the physes fuse at puberty ([@MCS003046TANC16]).

Approximately 90% of patients with SDS phenotypes have been found to carry pathogenic variants in the *SBDS* gene ([@MCS003046TANC28]). The SBDS protein promotes the activation of Elongation factor-like 1 (EFL1) in order for EFL1 to remove the antiassociation factor eIF6 and subsequently facilitate cytoplasmic maturation of the large (60S) ribosomal subunit ([@MCS003046TANC10]). *EFL1* variants have recently been implicated in an SDS-like phenotype (OMIM 617941) ([@MCS003046TANC24]). In the cohort of six patients reported with *EFL1* variants, half the patients presented with severe failure to thrive presumably due to untreated pancreatic insufficiency and died prior to age 15 mo ([@MCS003046TANC24]). The other three patients (ages 15 mo to 6 yr) manifested the hallmarks of SDS, including neutropenia (in isolation or with other bone marrow abnormalities), pancreatic insufficiency, and metaphyseal dysostosis ([@MCS003046TANC24]). In addition to EFL1, the DNAJC21 protein also plays a role in 60S ribosome maturation ([@MCS003046TANC18]) and has been associated with bone marrow failure (OMIM 617052; \[[@MCS003046TANC27]\]), as well as an SDS phenotype ([@MCS003046TANC7]). Thus, it is evident that ribosomopathies can include a spectrum of abnormalities with overlapping findings in organ systems such as the bone marrow, skeleton, and pancreas. Recently, variants in *SRP54*, which encodes a signal recognition particle involved in the translocation of nascent polypeptides, have also been implicated in the SDS phenotype ([@MCS003046TANC5]).

We report a 14-yr-old patient who was referred to the Undiagnosed Diseases Network (UDN; <https://undiagnosed.hms.harvard.edu/>) with a radiologic diagnosis of spondylometaphyseal dysplasia, corner fracture type, who also had a history of thrombocytopenia, growth failure, liver fibrosis, scoliosis, and learning difficulties. She had extensive clinical and molecular evaluations in the previous 12 years, including trio whole-exome sequencing (WES), without a unifying diagnosis. Exome reanalysis as part of the UDN revealed a homozygous missense variant in *EFL1*, which likely explains her phenotypic features and adds to the evidence of *EFL1* being associated with an SDS-like syndrome.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient is a 14-yr-old Caucasian female enrolled in the UDN with a previous clinical diagnosis of spondylometaphyseal dysplasia---corner fracture type and other multiple manifestations with no unifying diagnosis. There is a paternal family history of short stature. Her father is 5′4″, paternal grandmother was 4′11″, and paternal great-grandmother was 4′6″. The family history was otherwise noncontributory; the parents are not consanguineous. The patient was born at 39 wk gestational age following a pregnancy complicated by intrauterine growth restriction. Her birthweight was 1956 grams (\<5th percentile). Neonatal complications included thrombocytopenia (initial platelet count 82 × 10^9^/l, normal 140--300 × 10^9^/l) which improved to 108 × 10^9^/l on day of life 4. She first presented to endocrinology at 22 mo because of failure to thrive (height and weight below the third percentile) despite appropriate nutrition. A comprehensive endocrinology workup detected transaminitis and urine organic acids profile revealed a nonspecific pattern concerning for a possible mitochondrial disorder. Workup for mitochondrial disorder, including muscle and liver biopsies, was inconclusive. However, the liver biopsy did demonstrate moderate portal, periportal bridging, and centrilobular fibrosis ([Fig. 1](#MCS003046TANF1){ref-type="fig"}). Transient elevated transaminases were present at age 2--4 yr with no identified cause for the liver disease. Short stature failed to respond to growth hormone therapy.

![Liver biopsy showing decrease in liver fibrosis with age. Liver biopsy obtained at age 2 yr stained with (*A*) hematoxylin and eosin (H&E) and (*B*) Masson trichrome stain, and a liver needle biopsy obtained at age 14 yr stained with (*C*) H&E and (*D*) Masson trichrome stain. All 100× magnification.](MCS003046Tan_F1){#MCS003046TANF1}

Thrombocytopenia was mild and intermittent between the ages of 2 and 5 yr, but became persistent at age 6 yr when her platelet counts ranged from 45 to 136 × 10^9^/l. However, there were no clinical manifestations related to thrombocytopenia. She has never been neutropenic or anemic except for an episode of pancytopenia at age 9 yr with a fever and presumed viral illness. Bone marrow biopsy performed during this illness showed low cellularity (10%, normal for age ∼60%--70%) but no other specific abnormalities. Prior to age 2 yr, she had four episodes of pneumonia, but none required hospitalization, and she has not had recurrent infections since.

A skeletal survey at age 6 yr ([Fig. 2](#MCS003046TANF2){ref-type="fig"}) demonstrated mild S-shaped scoliosis, irregularity of the vertebral body endplates ([Fig. 2](#MCS003046TANF2){ref-type="fig"}A), metaphyseal irregularity of the femoral necks ([Fig. 2](#MCS003046TANF2){ref-type="fig"}B) and the left proximal humerus ([Fig. 2](#MCS003046TANF2){ref-type="fig"}C), irregularity of the bony acetabular roofs and iliac crests, and metaphyseal cupping involving the metacarpals of the hands (not shown), later classified as spondylometaphyseal dysplasia---corner fracture type, after review by the International Skeletal Dysplasia Registry (ISDR). She developed restrictive lung disease secondary to worsening scoliosis. The patient underwent surgery at age 13 yr to correct left genu varum.

![Skeletal anomalies on radiography. The three images on the *top* row were obtained at age 6 yr, and the three images on the lower row were obtained at age 14 yr. (*A*) Arrows show vertebrae with irregularity and scalloping subjacent to the disc spaces that are more pronounced in the radiograph (*D*) obtained at age 14 yr. (*B*) There is bilateral coxa vara and arrows demonstrate metaphyseal abnormalities of bilateral proximal femurs of mixed sclerosis and lucency. (*E*) Hip imaging at age 14 yr shows abnormal configuration (flattening) of the femoral heads, with continued metaphyseal heterogeneity in proximal and distal femurs (arrows). (*C*) Arrow on left proximal humerus shows heterogeneity in the ossification in the metaphysis (right humerus was normal; not shown). (*F*) Similar abnormal mixed sclerosis and lucency found in both humeri at age 14 yr (arrows).](MCS003046Tan_F2){#MCS003046TANF2}

The patient presented with hematuria at age 4 yr, which recurred at age 7 yr, with hypercalciuria on laboratory testing (24 h urine calcium 6.2 mg/kg/day, normal \<4 mg/kg/day). She was started on hydrochlorothiazide with resolution of urine calcium levels. Renal ultrasound examinations were normal. There were no developmental concerns in early childhood. Learning disabilities were diagnosed in the second grade, for which she received an Individualized Education Plan. She also had multiple dental caries that required full oral rehabilitation.

At age 14 yr, she was referred to the UDN and reanalysis of the previous WES data completed prior to her evaluation reported a homozygous variant in *EFL1*. Because of this finding, the patient\'s UDN evaluation was subsequently tailored to look for manifestations described in the prior report of *EFL1*-associated SDS-like phenotype ([@MCS003046TANC24]). At age 14 yr, her height and weight were below the first percentile. A repeat skeletal survey at age 14 yr demonstrated progression of the previously identified metaphyseal abnormalities ([Fig. 2](#MCS003046TANF2){ref-type="fig"}). Upon review by the ISDR and skeletal dysplasia experts at the Baylor School of Medicine within the UDN, the metaphyseal changes were thought to be consistent with SDS, but with greater severity than typically observed in these patients. A repeat bone marrow biopsy at age 14 yr demonstrated a hypocellular bone marrow (50%, normal for age ∼60%--70%) with trilineage hematopoiesis ([Fig. 3](#MCS003046TANF3){ref-type="fig"}) and no cytogenetic abnormalities. There was no history of intractable diarrhea. Evaluation for pancreatic insufficiency revealed high spot fecal fat (25%, normal \<20%), low serum amylase (18 U/l, normal 31--119 U/l) with normal stool pancreatic elastase and normal fat-soluble vitamin levels. Sample collection for 72-h fecal fat was not completed because of lack of patient compliance. The pancreas was not well visualized on abdominal ultrasound. Although her pancreatic phenotype was not completely delineated, she appeared to have mild pancreatic insufficiency based on history of failure to thrive and available laboratory assessments. A repeat liver biopsy showed regenerative changes, improved fibrosis with no inflammation or steatosis ([Fig. 1](#MCS003046TANF1){ref-type="fig"}), and liver enzymes and liver synthetic function were normal. Cognitive testing revealed a borderline IQ of 73 (4th %) on the Wechsler Abbreviated Scale of Intelligence Second Edition and specific impairments in perceptual-motor functioning and visual memory. She remains in a regular classroom with accommodations.

![Bone marrow biopsy at age 14 yr. Hypocellular bone marrow (50%) at (*A*) 40× and (*B*) 200× magnification, showing trilineage hematopoiesis (H&E stain). (*C*) Touch preparation showing normal maturation of the myeloid and erythroid lineages (500× magnification, Wright--Giemsa stain).](MCS003046Tan_F3){#MCS003046TANF3}

Genomic Analysis {#s2b}
----------------

Trio WES had been performed on a research basis ([@MCS003046TANC31]) at age 10 yr and was negative, with no variants of interest. On reanalysis of the WES data through the UDN in 2017, a homozygous missense variant (c.379 A\>G; p.Thr127Ala) in *EFL1* was identified ([Table 1](#MCS003046TANTB1){ref-type="table"}). The variant results in a nonconservative amino acid substitution in the GTP binding domain, which is located in the amino terminus of the protein ([Fig. 4](#MCS003046TANF4){ref-type="fig"}). The variant is absent from internal controls (13,119 samples) as well as the Exome Aggregation Consortium (ExAC) database (60,706 samples) ([@MCS003046TANC15]) and Exome Variant Server (EVS) database (6503 samples) (<http://evs.gs.washington.edu/EVS/>). One individual was heterozygous for this variant in gnomAD (1 allele out of 240,260), but it is absent in a homozygous state. The site is strongly conserved with the Genomic Evolutionary Rate Profiling (GERP++RS) score of 4.01 ([@MCS003046TANC6]). *EFL1* is intolerant to homozygous loss of function variants with a pREC score of 0.966 ([@MCS003046TANC15]). Multiple in silico tools, including CADD (25.9) ([@MCS003046TANC13]), PolyPhen (0.993) ([@MCS003046TANC1]), SIFT (0) ([@MCS003046TANC14]), and MutationTaster (D,1.0) ([@MCS003046TANC22]), predicted that the variant was damaging. Parental testing confirmed carrier status for each parent. No pathogenic variants were identified in the *SBDS* gene.

![Schematic of the EFL1 protein highlighting the GTP-binding domain (domain 1) ([@MCS003046TANC9]) in the amino terminus and the variants associated with human disease, as reported by the referenced articles. Numbers refer to amino acid position. G1--G5 refer to conserved motifs important for GTP binding ([@MCS003046TANC30]) (domains labeled according to [@MCS003046TANC2]).](MCS003046Tan_F4){#MCS003046TANF4}

###### 

*EFL1* variant information

  Gene     Chr: position GRCh37(hg19)   HGVS DNA reference       HGVS protein reference   Variant type   Predicted effect    Genotype    ClinVar accession  Inheritance
  -------- ---------------------------- ----------------------- ------------------------ -------------- ------------------ ------------ ------------------- -----------------------
  *EFL1*   Chr15: 82532896              NM_024580.5 c.379A\>G         p.Thr127Ala         Substitution       Missense       Homozygous    SCV000746595.2    Maternal and paternal

DISCUSSION {#s3}
==========

Disorders that affect ribosome production or function are referred to as ribosomopathies, of which SDS is one of the more well-known examples ([@MCS003046TANC20]). For the 10% of patients with manifestations of SDS who have no associated variants in the *SBDS* gene, next-generation sequencing has begun to uncover pathogenic variants in additional genes with similar functions who present with SDS-like phenotypes. Six patients from three families who presented with SDS-like features were identified by [@MCS003046TANC24] to have homozygous variants in the *EFL1* gene. These patients presented with developmental delay, failure to thrive, symptoms of pancreatic insufficiency, and cytopenias of one or more blood lineages ([@MCS003046TANC24]). The severity of the disorder was such that mortality was high, with three patients dying in childhood likely because of untreated pancreatic insufficiency. Metaphyseal anomalies were also observed on radiographs for all six patients ([@MCS003046TANC24]).

Contrary to the initial cohort of patients ([@MCS003046TANC24]) whose primary presentation was similar to SDS with growth failure and pancreatic insufficiency, our patient presented primarily with striking metaphyseal anomalies which worsened with age. Although she did have mild thrombocytopenia, the bone marrow manifestations had not been medically significant, with no documented episodes of neutropenia other than an episode of pancytopenia during a viral illness, nor has she needed transfusions. Additionally, the lack of overt pancreatic insufficiency resulted in lack of clinical recognition that she had an SDS-like phenotype, with the skeletal manifestations becoming the main diagnostic focus. [Table 2](#MCS003046TANTB2){ref-type="table"} compares the features in our patient and those of [@MCS003046TANC24].

###### 

Clinical features associated with *ELF1* variants

                             Stepensky et al. case series                                                                          Duke case
  -------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stature                    −2.6 to −4.8 SD                                                                                       −3.7 SD
  Head circumference         Normal in 2/6 patients (other 4 were from consanguineous families)                                    Normal
  Radiologic findings        Metaphyseal irregularities in proximal and distal femurs, fibulae, and humeri; anterior rib cupping   Metaphyseal irregularities in proximal and distal femurs, tibia, fibulae, humeri; flattening of hip epiphyses; iliac crest apophyseal irregularity; vertebral body endplate irregularities; scoliosis
  Pancreatic insufficiency   6/6 patients (5/6 with diarrhea)                                                                      No diarrhea; equivocal pancreatic laboratory results
  Liver disease              1 patient with mild hepatomegaly                                                                      Transaminitis (ages 2--4 yr) (AST 64--169 U/l; ALT 73--238 U/l)^a^; moderate portal, periportal bridging, and centrilobular fibrosis (age 2 yr)
  Anemia                     4/5 patients                                                                                          Absent; hemoglobin 11.1--12.1 g/dl^b,c^
  Neutropenia                4/5 patients                                                                                          Absent; ANC 1353--14874 cells/µl^c^
  Thrombocytopenia           4/5 patients                                                                                          Present; chronic since age 6 yr (platelets 96--136 × 10^9^/l)^c,d^
  Development                6/6 developmental delay                                                                               Learning disabilities in school
  Outcome                    3/6 deceased (ages 7 mo--15 mo); 3/6 alive (ages 15 mo to 6 yr)                                       Alive (age 14 yr)

SD, standard deviation; AST, aspartate transaminase; ALT, alanine transaminase; ANC, absolute neutrophil count.

^a^Reference ranges for AST: 10--60 U/l; ALT: 10--45 U/l.

^b^Reference ranges for hemoglobin: normal 11.5--13.5 g/dl ages 2--5 yr; 11.5--15.5 g/dl ages 6--11 yr; 12.0--16.0 g/dl ages 12--17 yr.

^c^Excluding blood counts obtained during episode of pancytopenia (see text).

^d^Reference range for platelet counts: normal 150--400 × 10^9^/l.

The identification of a homozygous *EFL1* variant led to further investigation of pancreatic insufficiency in our patient. The failure to gain weight could be related to pancreatic insufficiency, with laboratory findings of high fecal fat and low amylase, but the otherwise normal pancreatic tests could be indicative of mild insufficiency. Additional testing, including further imaging studies, and direct measurement of pancreatic enzymes are being considered, as well as a trial of enzyme supplementation. Our patient\'s hypercalciuria could also represent a manifestation of the *EFL1*-associated SDS phenotype. Renal lithiasis has been reported in patients with SDS ([@MCS003046TANC11]). Dental caries, as well as neurodevelopmental delays, as seen in our patient, are common as well ([@MCS003046TANC8]). Specific impairments in perceptual-motor functioning and visual memory are consistent with prior neurocognitive investigations in children with SDS ([@MCS003046TANC12]).

Patients with SDS have been reported to present with transaminitis, hyperbilirubinemia, hepatomegaly, and cirrhosis ([@MCS003046TANC26]). In one longitudinal study of 12 patients with SDS, the transaminitis resolved by age 5 yr, hepatomegaly by age 3 yr, and hyperbilirubinemia by age 4 yr, but elevated bile acids and hepatic microcysts were seen in some adult patients ([@MCS003046TANC26]). Our patient\'s mild transaminitis and fibrosis, with no sign of liver dysfunction after age 4 yr, is certainly consistent with the SDS phenotype, although none of the six patients reported previously had liver dysfunction except for one patient with mild hepatomegaly ([@MCS003046TANC24]). The diagnosis in our patient has medical management implications such as periodic monitoring for hematological malignancies and possible treatment for mild pancreatic insufficiency to determine if it would help with growth.

Interestingly, all the patients in the prior report had variants associated with the carboxyl terminus of the protein, and [@MCS003046TANC24] observed that these mutant protein variants fail to release eIF6 from the 60S subunit, hence interrupting the formation of mature ribosomes. Our variant is located near the amino terminus of the protein ([Fig. 4](#MCS003046TANF4){ref-type="fig"}) and results in a missense, nonconservative amino acid substitution in the EFL1 protein within the GTP-binding domain ([@MCS003046TANC9]). This variant may hence affect the GTPase function of EFL1, although we are not able to confirm the actual functional change conferred by the variant without functional assays. Perhaps the variants being in different regions of the protein result in phenotypic differences in our patient compared with the previously reported patients with *EFL1* pathogenic variants ([@MCS003046TANC24]), although it is worth noting that there is little genotype--phenotype correlation even for well-studied ribosomopathies such as SDS ([@MCS003046TANC19]).

The features of our patient and the other six patients with *EFL1* biallelic variants may be representative of a SDS-like disorder or may be indicative of the genetic heterogeneity of SDS, which until recently has been known to be associated with only one gene. Further literature reports will help clarify if these are distinct ribosomopathies with overlapping features or could be classified as one entity.

Using American College of Medical Genetics and Genomics (ACMG) variant classification guidelines ([@MCS003046TANC21]), the *EFL1* variant is denoted as a variant of uncertain significance. Using the ClinGen Gene-Disease Association curation framework ([@MCS003046TANC25]) with protocol updates published on the ClinGen website ([www.clinicalgenome.org](www.clinicalgenome.org)), the evidence supporting an association between *EFL1* and SDS-like syndrome is currently considered "limited." However, considering the functional interaction of SBDS with EFL1, as well as our patient\'s overlap with features of SDS and SDS-like phenotypes in unrelated individuals with *EFL1* variants ([@MCS003046TANC24]), we strongly favor that the homozygous *EFL1* variant is a likely diagnosis for our patient. The combination of uncommon clinical features in our patient---that is, both spondylometaphyseal dysplasia (population prevalence estimated to be at 1/100,000; [www.orpha.net](www.orpha.net)) and childhood exocrine pancreatic insufficiency (cystic fibrosis tested and excluded; not shown)---also argues for a diagnosis of an SDS-like syndrome. In addition, we note that the ACMG variant classification guidelines are specifically developed to assess pathogenicity in well-characterized disease genes or variants that occur de novo in a patient; both of which are not applicable in this case. We find the ClinGen curation framework useful in assessing gene-disease relationships, and we believe that evidence for *EFL1*-SDS syndrome association will be stronger with the inclusion of more cases and functional data.

A notable finding with our patient is that the *EFL1* variant was not initially prioritized from the exome data obtained in 2013. The *EFL1* gene was not associated with human disease at the time, but EFL1 was known to interact physically with SBDS and function epistatically in yeast ([@MCS003046TANC17]) and to release eIF6 in mammalian cells ([@MCS003046TANC9]) in pre-60S ribosomal processing. The research laboratory that performed and analyzed the sequence data utilizes an agnostic approach to the genome, but despite the strong bioinformatics signatures, this variant was not reported. Retrospectively, it is difficult to determine the exact reason for this, but it could be related to the focus of the laboratory at that time on de novo variants. It is certainly very plausible that this variant would also not have been reported by clinical laboratories, given the lack of association with human disease until very recently. Indeed, many of the cases that get resolved with WES reanalyses are due to interim new gene-disease associations ([@MCS003046TANC29]). Thus, this experience adds credence to the value of WES reanalysis when the initial report is negative.

In conclusion, our report provides further clinical and genomic evidence for *EFL1* being associated with an SDS-like phenotype, highlighting the phenotypic variability that can occur. It also illustrates the current conundrum within genomic medicine of bioinformatically compelling variants not being prioritized in WES data, emphasizing the value of WES reanalysis when a diagnosis is not evident initially.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

The sequence data were reanalyzed using our established trio sequencing protocols ([@MCS003046TANC31]) that identifies qualifying variants forming novel genotypes not observed in the parents or in a set of 13,119 controls or external databases provided by the Exome Sequencing Project (ESP6500SI) (NHLBI GO Exome Sequencing Project; evs.gs.washington.edu), and the Exome Aggregation Consortium ([@MCS003046TANC15]). Samples sequenced at the Institute for Genomic Medicine (IGM) (previously the Center for Human Genome Variation at Duke University) were collected as peripheral blood. Exome enrichment was done using the SeqCap EZ Exome v3 (Roche Nimblegen, Madison, WI). Sequencing was performed in the Genomic Analysis Facility on an Illumina HiSeq 2000. Please see [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003046/-/DC1) for sequencing coverage.

Our standard bioinformatics pipeline was used to analyze data. Briefly, the pipeline uses GATK best practices, utilizing BWA 0.5.1023, picard tools 1.59, and the Unified Genotyper from GATK 1.6-1124--26. Reads are aligned to the hg19 reference sequence utilized in 1000 genomes phase 2, which includes EBV derived decoy sequences. Variant calls are functionally annotated with SnpEff 3.327 using Ensembl build 73. All samples are processed individually through the bioinformatics pipeline and single sample calling is performed.

Variant calls are loaded into our internal mysql database AnnoDB and further analyzed using our software Analysis Tool for Annotated Variants (ATAV). Newly homozygous calls are made by comparing proband variant calls to parents and ensuring both parents have a high quality heterozygous call at the site.

Members of the Undiagnosed Diseases Network {#s4b}
===========================================

Mercedes E. Alejandro,[14](#FN14){ref-type="fn"} Mahshid S. Azamian,[14](#FN14){ref-type="fn"} Carlos A. Bacino,[14](#FN14){ref-type="fn"} Ashok Balasubramanyam,[14](#FN14){ref-type="fn"} Bret L. Bostwick,[14](#FN14){ref-type="fn"} Lindsay C. Burrage,[14](#FN14){ref-type="fn"} Shan Chen,[14](#FN14){ref-type="fn"} Gary D. Clark,[14](#FN14){ref-type="fn"} William J. Craigen,[14](#FN14){ref-type="fn"} Shweta U. Dhar,[14](#FN14){ref-type="fn"} Lisa T. Emrick,[14](#FN14){ref-type="fn"} Alica M. Goldman,[14](#FN14){ref-type="fn"} Neil A. Hanchard,[14](#FN14){ref-type="fn"} Fariha Jamal,[14](#FN14){ref-type="fn"} efkothea Karaviti,[14](#FN14){ref-type="fn"} Seema R. Lalani,[14](#FN14){ref-type="fn"} Brendan H. Lee,[14](#FN14){ref-type="fn"} Richard A. Lewis,[14](#FN14){ref-type="fn"} Ronit Marom,[14](#FN14){ref-type="fn"} Paolo M. Moretti,[14](#FN14){ref-type="fn"} David R. Murdock,[14](#FN14){ref-type="fn"} Sarah K. Nicholas,[14](#FN14){ref-type="fn"} Jordan S. Orange,[14](#FN14){ref-type="fn"} James P. Orengo,[14](#FN14){ref-type="fn"} Jennifer E. Posey,[14](#FN14){ref-type="fn"} Lorraine Potocki,[14](#FN14){ref-type="fn"} Jill A. Rosenfeld,[14](#FN14){ref-type="fn"} Susan L. Samson,[14](#FN14){ref-type="fn"} Daryl A. Scott,[14](#FN14){ref-type="fn"} Alyssa A. Tran,[14](#FN14){ref-type="fn"} Tiphanie P. Vogel,[14](#FN14){ref-type="fn"} Hugo J. Bellen,[14](#FN14){ref-type="fn"},[15](#FN15){ref-type="fn"} Michael F. Wangler,[14](#FN14){ref-type="fn"},[15](#FN15){ref-type="fn"} Shinya Yamamoto,[14](#FN14){ref-type="fn"},[15](#FN15){ref-type="fn"} Christine M. Eng,[14](#FN14){ref-type="fn"} Donna M. Muzny,[14](#FN14){ref-type="fn"} Patricia A. Ward,[14](#FN14){ref-type="fn"} Yaping Yang,[14](#FN14){ref-type="fn"} David B. Goldstein,[16](#FN16){ref-type="fn"} Nicholas Stong,[16](#FN16){ref-type="fn"} Heidi Cope,[17](#FN17){ref-type="fn"} Yong-hui Jiang,[17](#FN17){ref-type="fn"} Allyn McConkie-Rosell,[17](#FN17){ref-type="fn"} Loren D.M. Pena,[17](#FN17){ref-type="fn"} Kelly Schoch,[17](#FN17){ref-type="fn"} Vandana Shashi,[17](#FN17){ref-type="fn"} Rebecca C. Spillmann,[17](#FN17){ref-type="fn"} Jennifer A. Sullivan,[17](#FN17){ref-type="fn"} Queenie K.-G. Tan,[17](#FN17){ref-type="fn"} Nicole M. Walley,[17](#FN17){ref-type="fn"} Aday Aaron,[18](#FN18){ref-type="fn"} Alan H. Beggs,[18](#FN18){ref-type="fn"} Gerard T. Berry,[18](#FN18){ref-type="fn"} Lauren C. Briere,[18](#FN18){ref-type="fn"} Cynthia M. Cooper,[18](#FN18){ref-type="fn"} Laurel A. Donnell-Fink,[18](#FN18){ref-type="fn"} Elizabeth L. Fieg,[18](#FN18){ref-type="fn"} Frances High,[18](#FN18){ref-type="fn"} Susan Korrick,[18](#FN18){ref-type="fn"} Joel B. Krier,[18](#FN18){ref-type="fn"} Sharyn A. Lincoln,[18](#FN18){ref-type="fn"} Joseph Loscalzo,[18](#FN18){ref-type="fn"} Richard L. Maas,[18](#FN18){ref-type="fn"} Calum A. MacRae,[18](#FN18){ref-type="fn"} J. Carl Pallais,[18](#FN18){ref-type="fn"} Lance H. Rodan,[18](#FN18){ref-type="fn"} Edwin K. Silverman,[18](#FN18){ref-type="fn"} Joan M. Stoler,[18](#FN18){ref-type="fn"} David A. Sweetser,[18](#FN18){ref-type="fn"} Melissa Walker,[18](#FN18){ref-type="fn"} Chris A. Walsh,[18](#FN18){ref-type="fn"} Cecilia Esteves,[18](#FN18){ref-type="fn"} Emily Glanton,[18](#FN18){ref-type="fn"} Ingrid A. Holm,[18](#FN18){ref-type="fn"} Isaac S. Kohane,[18](#FN18){ref-type="fn"} Alexa T. McCray,[18](#FN18){ref-type="fn"} Matthew Might,[18](#FN18){ref-type="fn"} Kimberly LeBlanc,[18](#FN18){ref-type="fn"} David P. Bick,[19](#FN19){ref-type="fn"} Camille L. Birch,[19](#FN19){ref-type="fn"} Braden E. Boone,[19](#FN19){ref-type="fn"} Donna M. Brown,[19](#FN19){ref-type="fn"} Daniel C. Dorset,[19](#FN19){ref-type="fn"} Angela L. Jones,[19](#FN19){ref-type="fn"} Jozef Lazar,[19](#FN19){ref-type="fn"} Shawn E. Levy,[19](#FN19){ref-type="fn"} Thomas May,[19](#FN19){ref-type="fn"} J. Scott Newberry,[19](#FN19){ref-type="fn"} Elizabeth A. Worthey,[19](#FN19){ref-type="fn"} Gabriel F. Batzli,[20](#FN20){ref-type="fn"} Heather A. Colley,[20](#FN20){ref-type="fn"} Jyoti G. Dayal,[20](#FN20){ref-type="fn"} David J. Eckstein,[20](#FN20){ref-type="fn"} Sarah E. Gould,[20](#FN20){ref-type="fn"} Ellen M. Howerton,[20](#FN20){ref-type="fn"} Donna M. Krasnewich,[20](#FN20){ref-type="fn"} Laura A. Mamounas,[20](#FN20){ref-type="fn"} Teri A. Manolio,[20](#FN20){ref-type="fn"} John J. Mulvihill,[20](#FN20){ref-type="fn"} Tiina K. Urv,[20](#FN20){ref-type="fn"} Anastasia L. Wise,[20](#FN20){ref-type="fn"} Matthew Brush,[21](#FN21){ref-type="fn"} Jean-Philippe F. Gourdine,[21](#FN21){ref-type="fn"} Melissa Haendel,[21](#FN21){ref-type="fn"} David M. Koeller,[21](#FN21){ref-type="fn"} Jennifer E. Kyle,[22](#FN22){ref-type="fn"} Thomas O. Metz,[22](#FN22){ref-type="fn"} Katrina M. Waters,[22](#FN22){ref-type="fn"} Bobbie-Jo M. Webb-Robertson,[22](#FN22){ref-type="fn"} Euan A. Ashley,[23](#FN23){ref-type="fn"} Jonathan A. Bernstein,[23](#FN23){ref-type="fn"} Devon Bonner,[23](#FN23){ref-type="fn"} Terra R. Coakley,[23](#FN23){ref-type="fn"} Jean M. Davidson,[23](#FN23){ref-type="fn"} Annika M. Dries,[23](#FN23){ref-type="fn"} Gregory M. Enns,[23](#FN23){ref-type="fn"} Liliana Fernandez,[23](#FN23){ref-type="fn"} Paul G. Fisher,[23](#FN23){ref-type="fn"} Noah D. Friedman,[23](#FN23){ref-type="fn"} Jason Hom,[23](#FN23){ref-type="fn"} Yong Huang,[23](#FN23){ref-type="fn"} Jennefer N. Kohler,[23](#FN23){ref-type="fn"} Marta M. Majcherska,[23](#FN23){ref-type="fn"} Shruti Marwaha,[23](#FN23){ref-type="fn"} Colleen E. McCormack,[23](#FN23){ref-type="fn"} Jason D. Merker,[23](#FN23){ref-type="fn"} Chloe M. Reuter,[23](#FN23){ref-type="fn"} Jacinda B. Sampson,[23](#FN23){ref-type="fn"} Kevin S. Smith,[23](#FN23){ref-type="fn"} Daryl M. Waggott,[23](#FN23){ref-type="fn"} Matthew T. Wheeler,[23](#FN23){ref-type="fn"} Diane B. Zastrow,[23](#FN23){ref-type="fn"} Chunli Zhao,[23](#FN23){ref-type="fn"} Patrick Allard,[24](#FN24){ref-type="fn"} Hayk Barseghyan,[24](#FN24){ref-type="fn"} Manish J. Butte,[24](#FN24){ref-type="fn"} Esteban C. Dell\'Angelica,[24](#FN24){ref-type="fn"} Katrina M. Dipple,[24](#FN24){ref-type="fn"} Naghmeh Dorrani,[24](#FN24){ref-type="fn"} Emilie D. Douine,[24](#FN24){ref-type="fn"} Ascia Eskin,[24](#FN24){ref-type="fn"} Brent L. Fogel,[24](#FN24){ref-type="fn"} Hane Lee,[24](#FN24){ref-type="fn"} Sandra K. Loo,[24](#FN24){ref-type="fn"} Martin G. Martin,[24](#FN24){ref-type="fn"} Julian A. Martínez-Agosto,[24](#FN24){ref-type="fn"} Stan F. Nelson,[24](#FN24){ref-type="fn"} Christina GS. Palmer,[24](#FN24){ref-type="fn"} Jeanette C. Papp,[24](#FN24){ref-type="fn"} Neil H. Parker,[24](#FN24){ref-type="fn"} Rebecca Signer,[24](#FN24){ref-type="fn"} Janet S. Sinsheimer,[24](#FN24){ref-type="fn"} Eric Vilain,[24](#FN24){ref-type="fn"} Jijun Wan,[24](#FN24){ref-type="fn"} Amanda J. Yoon,[24](#FN24){ref-type="fn"} Allison Zheng,[24](#FN24){ref-type="fn"} Babak Behnam,[25](#FN25){ref-type="fn"} Elizabeth A. Burke,[25](#FN25){ref-type="fn"} Precilla D\'Souza,[25](#FN25){ref-type="fn"} Mariska Davids,[25](#FN25){ref-type="fn"} David D. Draper,[25](#FN25){ref-type="fn"} Tyra Estwick,[25](#FN25){ref-type="fn"} Carlos Ferreira,[25](#FN25){ref-type="fn"} Rena A. Godfrey,[25](#FN25){ref-type="fn"} Catherine A. Groden,[25](#FN25){ref-type="fn"} Jean M. Johnston,[25](#FN25){ref-type="fn"} C. Christopher Lau,[25](#FN25){ref-type="fn"} Ellen F. Macnamara,[25](#FN25){ref-type="fn"} Valerie V. Maduro,[25](#FN25){ref-type="fn"} Thomas C. Markello,[25](#FN25){ref-type="fn"} Marie Morimoto,[25](#FN25){ref-type="fn"} Jennifer L. Murphy,[25](#FN25){ref-type="fn"} Michele E. Nehrebecky,[25](#FN25){ref-type="fn"} Donna Novacic,[25](#FN25){ref-type="fn"} Barbara N. Pusey,[25](#FN25){ref-type="fn"} Prashant Sharma,[25](#FN25){ref-type="fn"}CamiloToro[25](#FN25){ref-type="fn"} Colleen E. Wahl,[25](#FN25){ref-type="fn"} Guoyun Yu,[25](#FN25){ref-type="fn"} Andrea L. Gropman,[25](#FN25){ref-type="fn"},[26](#FN26){ref-type="fn"} Eva Baker,[25](#FN25){ref-type="fn"} David R. Adams,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} William A. Gahl,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} May Christine V. Malicdan,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} Cynthia J. Tifft,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} Lynne A. Wolfe,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} John Yang,[25](#FN25){ref-type="fn"},[27](#FN27){ref-type="fn"} John H. Postlethwait,[28](#FN28){ref-type="fn"} Monte Westerfield,[28](#FN28){ref-type="fn"} Anna Bican,[29](#FN29){ref-type="fn"} Elly Brokamp,[29](#FN29){ref-type="fn"} Laura Duncan,[29](#FN29){ref-type="fn"} Rizwan Hamid,[29](#FN29){ref-type="fn"} Mary Kozuira,[29](#FN29){ref-type="fn"} John H. Newman,[29](#FN29){ref-type="fn"} John A. Phillips III,[29](#FN29){ref-type="fn"} Lynette Rives,[29](#FN29){ref-type="fn"} Amy K. Robertson,[29](#FN29){ref-type="fn"} Lisa Shakachite,[29](#FN29){ref-type="fn"} Joy D. Cogan,[29](#FN29){ref-type="fn"}
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